All 1 tracked stories fall under one category: pharma. China is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Suzhou BioBay appears in 1 tracked Biotech story from March 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Suzhou BioBay
All 1 tracked stories fall under one category: pharma. China is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Suzhou BioBay appears in 1 tracked Biotech story from March 18, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Suzhou BioBay. Shared-story counts are live from our verified record — not editorial picks.
China's launch of its 15th Five-Year Roadmap has triggered a strategic shift in foreign investment toward high-tech sectors, with biotechnology emerging as a primary beneficiary. Global pharmaceutical giants and venture funds are recalibrating their portfolios to align with Beijing’s 'New Quality Productive Forces' initiative.
Suzhou BioBay is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.